Lung Cancer Considered

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Fawzi Abu Rous, Dr. Raid Aljumaily, Dr. Abdulaziz AlJassim, and Dr. Ashraf Mohamed. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guests: Dr. Fawzi Abu Rous Thoracic Medical Oncologist Henry Ford Health, Detroit, MI Dr. Raid Aljumaily Associate Professor of Medicine University of Oklahoma Dr. Abdulaziz AlJassim Senior Specialist in Thoracic Medical Oncology and Internal Medicine. Kuwait Cancer Control Center, Kuwait Dr. Ashraf Mohamed Director of Surgery Business Development Siemens Healthineers

This episode of Lung Cancer Considered covers the recently completed 2024 ESMO Congress in Barcelona. Host Dr. Stephen Liu discussed the important research presented at the meeting with Dr. Marina Garassino and Dr. Federico Cappuzzo.

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair

In this episode of Lung Cancer Consider, host Dr. Stephen Liu previews the upcoming IASLC 2024 Asia Conference on Lung Cancer with meeting co-chair, Dr. Feng-Ming (Spring) Kong.

Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by clinicians Guest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical Center Guest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Isabella Favato Barcelos and Dr. William Nassib William. Guests: Dr. Clarissa Mathias Medical Oncologist at Oncoclinicas Bahia and Hospital Santa Izabel Dr. Isabella Favato Barcelos Medical Oncologist, Oncoclinicas&Co/MedSir, Brazil Dr. William Nassib William National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conference on Lung Cancer as nurse practitioners. Hear their favorite sessions, their observations as first-time attendees, and why they hope to see more nurse practitioners at future IASLC events. Guests: Jillian Thompson, MSN, ANP-BC, AOCNP Nurse Practitioner MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center Stephanie McDonald RN, MSN, FNP-BC, AOCNP Nurse Practitioner Dana-Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Coral Olazagasti moderates a discussion in Spanish about highlights from the conference with Dr. Maria Velez and Dr. Rossana Ruiz. Guests: Dr. Coral Olazagasti Assistant Professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Rossana Ruiz Medical Oncologist from Universidad Peruana Cayetano Heredia Global Health Fellowship at MGH in Boston, Massachusetts Thoracic Medical Oncologist, Instituto Nacional de Enfermedades Neoplasicas and AUNA-Oncosalud in Lima, Peru Dr. Maria Velez Clinical Instructor, Division of Hematology-Oncology UCLA David Geffen School of Medicine in Los Angeles, California

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain. Guests: Dr. Hidehito Horinouchi Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo General Secretary, Japan Clinical Oncology Group Dr. Noemi Reguart Clinical Professor at the University of Barcelona Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain WCLC 2025 Co-Chair Dr. Jacob Sands Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang and Dr. Lin Wu. Guests: Dr. Chunxia Su Professor of Oncology at Tongji University Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital Dr. Huijuan Wang Professor of Oncology Department of Medical Oncology The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital Dr. Lin Wu Director, Thoracic Oncology Department II Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC. Guests: Dr. Fiona Hegi-Johnson Radiation Oncologist at the Peter MacCallum Cancer Centre Senior Research Fellow at the University of Melbourne Dr. Xiuning Le, M.D., Ph.D. Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology University of Texas M.D. Anderson Cancer Center Dr. Gerrina Ruiter, M.D., Ph.D. Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer Institute Amsterdam, The Netherlands

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Jii Bum (Joy) Lee. Guests: Dr. Chul Kim, MD Associate Professor at Georgetown University with a focus on thoracic oncology Dr. Jeongmin Seo, MD Clinical Assistant Professor at Seoul National University Bundang Hospital with a focus on thoracic oncology Dr. Jii Bum (Joy) Lee, MD, PhD Yonsei Cancer Center, Yonsei University College of Medicine

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference. Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018. Guests: Dr. Tina Cascone Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center in Houston, Texas Dr. Marina Chiara Garassino Director, Thoracic Oncology Program and Professor of Medicine University of Chicago Dr. Matthew Smeltzer Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health University of Memphis Professor Caicun Zhou Chief Physician and Director of the Department of Medical Oncology Tongji University in Shanghai Pulmonary Hospital

Description: To celebrate IASLC’s 50th Anniversary, IASLC produced podcasts looking at our past and present. In this podcast, host Dr. Narjust Florez peers into the future with a detailed discussion of the new IASLC Strategic Plan and how it will impact IASLC as well as the future of lung cancer care. Guest: Dr. Nick Pavlakis is a thoracic medical oncologist and professor of medicine at the University of Sydney. Guest: Dr. Gilberto Lopes is the Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, Associate Director for the Cancer Center and Medical Director for International Affairs and Professor of Medicine at the University of Miami.

Description: This year marks the 50th anniversary of the International Association for the Study of Lung Cancer and as part of this celebratory year, we are looking at the past, present and future of the organization. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests focus on IASLC today – and some of the ongoing efforts of the IASLC and its members. Guest: Dr. Christian Rolfo, Professor of Medicine, Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at the Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University. Guest: Janet Freeman-Daily, Patient Research Advocate, Co-Founder and President of The ROS1ders, former Associate Editor of IASLC Lung Cancer News and co-developer of the IASLC STARS program. Guest: Dr. Emily Stone is a Consultant Respiratory Physician at St. Vincent’s Hospital in Sydney Australia, conjoint Professor at the University of New South Wales, past Chair of the IASLC Tobacco Control and Smoking Cessation Committee, Deputy Chair Thoracic Oncology Group of Australasia and current Editor in Chief of the JTO Clinical and Research Reports

In 1972, in response to the overwhelming need for collaboration and a growing concern for public health, Drs. David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain and George Higgins began building an international, multidisciplinary organization. In 1974, the group launched the International Association for the Study of Lung Cancer (IASLC) at their first formal meeting in Florence, Italy, having recruited more than 250 founding members from across the globe and with different perspectives. In today’s episode, host Dr. Narjust Florez talks with two of those early members who played influential roles in IASLC’s early growth and success: Dr. Paul Bunn and Dr. Fred Hirsch. Guest: Dr. Paul Bunn is a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of Colorado School of Medicine. Dr Bunn was President of the ASCO and he served as president and as CEO, of the International Association for the Study of Lung Cancer. Guest: Dr. Hirsch is the Executive Director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Dr. Hirsch served as Chief Executive Officer of IASLC for five years.

Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab.. Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.

As part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who discuss current research and clinical issues, in Mandarin. Host: Chunxia Su, M.D., PhD, Professor of Oncology, Doctoral Supervisor, School of Medicine, Tongji University Guest: Xiuning Le, MD, Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine, MD Anderson Guest: Jianming Ying, Professor & Director Department of Pathology National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Guest: Professor Li Zhang, Director of the Department of Internal Medicine, Doctoral Supervisor, Second Class Professor, and Chief Expert on Lung Cancer at Sun Yat sen University Cancer Prevention and Treatment Center

Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting’s other three co-chairs. Guest: Dr. Linda Martin, Professor of Surgery and Chief of Thoracic Surgery at the University of Virginia. Guest: Dr. Fabio Ynoe de Moraes, Chief of Global Radiation Oncology and Associate Professor of Radiation Oncology at Queen University. Guest: Dr. Sandip Patel, Professor of Medicine and Thoracic Medical Oncologist at the University of California San Diego.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherapy and how recent research may affect clinical decision making in Latin America. Guest: Dr. Clarissa Baldotto graduated from the Fluminense Federal University and studied Clinical Oncology at the National Cancer Institute (INCA). She completed a Master's Degree in Clinical Cancerology at INCA and a PhD in Medical Sciences at the D'Or Institute for Research and Education (ID'Or). Guest: Dr. Paula Ugalde Figueroa graduated from the School of Medicine at the Federal University of Bahia in Salvador, BA, Brazil. With training in Brazil, the United States, and Canada, Dr. Ugalde has established herself as a research-driven thoracic surgeon. In 2021, she was appointed as a Director of the IASLC Board of Directors and continues to break barriers for many Latinas in oncology.